1226548-17-9

Upstream product

• 946198-89-6 tert-butyl 4-chloro-5,6-dihydropyrido(4’,3’:4,5)thieno(2,3-d)pyrimidine-7(8H)-carboxylate 
• 20989-17-7 (2S)-2-phenylglycinol 
• 874801-60-2 tert-butytert-butyl-4-oxo-3,4,5,6,7,8-hexahydropyrido[4′,3′:4,5]thieno-[2,3-d]pyrimidine-7-carboxylatel-4-oxo-3,4,5,6,7,8-hexahydropyrido[4′,3′:4,5]thieno-[2,3-d]pyrimidine-7-carboxylate 
• 193537-14-3 2-amino-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3,6-dicarboxylic acid 6-tert-butyl ester 3-ethyl ester 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 

Downstream Products

• 1226548-19-1 (S)-2-phenyl-2-((5,6,7,8-tetrahydropyrido[4’,3’:4,5]thieno[2,3-d]pyrimidin-4-yl)amino)ethan-1-ol 

Relevant academic research and scientific papers

PET probe detecting non-small cell lung cancer susceptible to epidermal growth factor receptor tyrosine kinase inhibitor therapy

Tyrosine kinase inhibitors for epidermal growth factor receptor (EGFR-TKIs) are used as molecular targeted therapy for non-small cell lung cancer (NSCLC) patients. The therapy is applied to the patients having EGFR-primary L858R mutation, but drug toleran

Nuclear Medicine Diagnostic Imaging Agent

Provided is a radioactive labeled compound capable of detecting a secondary mutation of an epidermal growth factor receptor, where the compound is represented by Formula (1) or a pharmaceutically acceptable salt thereof, where R1, R2

Fused Bicyclic and Tricyclic Pyrimidine Compounds as Tyrosine Kinase Inhibitors

Fused bicyclic or tricyclic compounds of formula (I): wherein A, B, C, X, Y, m, and n are defined herein. Also disclosed are a method for inhibiting EGFR kinase activity and a method for treating cancer with these compounds.

Design and synthesis of tetrahydropyridothieno[2,3-d]pyrimidine scaffold based epidermal growth factor receptor (EGFR) kinase inhibitors: The role of side chain chirality and michael acceptor group for maximal potency

HTS hit 7 was modified through hybrid design strategy to introduce a chiral side chain followed by introduction of Michael acceptor group to obtain potent EGFR kinase inhibitors 11 and 19. Both 11 and 19 showed over 3 orders of magnitude enhanced HCC827 a